Advertisement

Iatrogenic Pharmaceutical Amyloidosis Associated with Insulin and Enfuvirtide Administration

  • Ahmet DoganEmail author
  • Oana Madalina Mereuta
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Drug-induced amyloidosis is a rare form of iatrogenic amyloidosis and represents a localized process. Insulin and Enfuvirtide are two peptide drugs which may cause localized amyloidosis after prolonged use (i.e., AIns and AEnf, respectively) commonly identified as abdominal subcutaneous masses at the injection site. In particular, self-assembled aggregation process of insulin is known to occur at certain conditions leading to impaired systemic absorption through the amyloid plaques and, in some cases, severe insulin resistance. Moreover, AIns can be misdiagnosed as systemic immunoglobulin-derived amyloidosis especially when the clinical context is unknown or the patient presents a monoclonal gammopathy. Enfuvirtide is a new antiretroviral agent termed “fusion inhibitor” and used for the treatment of HIV-1 infection. The injection site reactions to Enfuvirtide are frequent. Therefore, precise amyloid typing by immunohistochemistry (IHC) and/or mass spectrometry-based proteomics is required for diagnosis of iatrogenic amyloidosis and bears clinical significance.

Keywords

Insulin-derived amyloidosis (AIns) Diabetes Enfuvirtide Injection site reactions 

References

  1. 1.
    Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Storkel S, Schneider HM, Muntefering H, Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest. 1983;48:108–11.PubMedGoogle Scholar
  4. 4.
    Morilla ME, Kocher J, Harmaty M. Localized amyloidosis at the site of enfuvirtide injection. Ann Intern Med. 2009;151:515–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Naujokas A, Vidal CI, Mercer SE, Harp J, Kurtin PJ, Fox LP, et al. A novel form of amyloid deposited at the site of enfuvirtide injection. J Cutan Pathol. 2012;39:220–1. Quiz 19.CrossRefPubMedGoogle Scholar
  6. 6.
    Amdursky N, Gazit E, Rosenman G. Formation of low-dimensional crystalline nucleus region during insulin amyloidogenesis process. Biochem Biophys Res Commun. 2012;419:232–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Landreh M, Stukenborg JB, Willander H, Soder O, Johansson J, Jornvall H. Proinsulin C-peptide interferes with insulin fibril formation. Biochem Biophys Res Commun. 2012;418:489–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Westermark P, Eizirik DL, Pipeleers DG, Hellerstrom C, Andersson A. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia. 1995;38:543–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Swift B, Hawkins PN, Richards C, Gregory R. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med. 2002;19:881–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Nagase T, Katsura Y, Iwaki Y, Nemoto K, Sekine H, Miwa K, et al. The insulin ball. Lancet. 2009;373:184.CrossRefPubMedGoogle Scholar
  11. 11.
    D’Souza A, Theis JD, Vrana JA, Buadi F, Dispenzieri A, Dogan A. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012;87:E131–2.CrossRefPubMedGoogle Scholar
  12. 12.
    D’Souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid. 2014;21:71–5.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53:678–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Mirza RA, Turiansky GW. Enfuvirtide and cutaneous injection-site reactions. J Drugs Dermatol. 2012;11:e35–8.PubMedGoogle Scholar
  15. 15.
    Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Departments of Pathology and Laboratory MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations